Employing Biogenic Reduced Graphene Oxide as an Antibacterial Agent Against Some MDR Pathogenic Bacterial Isolates

Abstract

Antibiotic resistance in pathogenic microbes has become a severe health issue worldwide. Consequently, hard work has been made to progress novel materials with antimicrobial effectiveness. Current research accomplished to investigate the efficiency of biogenic reduced graphene oxide nanoparticles which were reduced for the first time by two bacterial strains Heyndirckxia coagulans (accession no. PP425868.1) and Streptococcus thermophilus (accession no. PP425862.1). The biosynthesized rGO NPs appeared to have antibacterial activity against (Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumonia, and Pantoea agglomerans), which were isolated from burns and wounds and urinary tract infections. Different concentrations of rGO NPs (0.05, 0.1, and 0.2 mg/ml) have been applied against the above MDR bacterial isolates. Results revealed that the development of inhibition areas augmented with the increase of rGO NPs concentration compared to the Ampicillin antibiotic. Using rGO NPs as antibacterial agents for curing infections associated with MDR bacteria is developing owing to exceptional physicochemical features such as high surface area, shape, and biocompatibility of rGO NPs.